CR20110606A - Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales - Google Patents

Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales

Info

Publication number
CR20110606A
CR20110606A CR20110606A CR20110606A CR20110606A CR 20110606 A CR20110606 A CR 20110606A CR 20110606 A CR20110606 A CR 20110606A CR 20110606 A CR20110606 A CR 20110606A CR 20110606 A CR20110606 A CR 20110606A
Authority
CR
Costa Rica
Prior art keywords
tau
antibody
treatment
brain diseases
phosphorylated
Prior art date
Application number
CR20110606A
Other languages
English (en)
Inventor
Bernd Bohrmann
Ulrich Goepfert
Fiona Grueninger
Walter Huber
Hans-Willi Krell
Valeria Lifke
Olaf Mundigl
Sonja Offner
Laurence Ozmen
Michael Schraeml
Original Assignee
Cargill Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cargill Inc, Hoffmann La Roche filed Critical Cargill Inc
Publication of CR20110606A publication Critical patent/CR20110606A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un anticuerpo, que se une a la tau fosforilada en la serina 422 (pS422), caracterizado porque se une específicamente al fragmento tau fosforilado de la SEQ ID NO: 9 y a la tau pS422, pero no se une a la tau ni al fragmento MCAK fosforilado de la SEQ ID NO: 17, es útil para el tratamiento de una tauopatía.
CR20110606A 2009-06-10 2011-11-16 Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales CR20110606A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09007656 2009-06-10
EP09008487 2009-06-30

Publications (1)

Publication Number Publication Date
CR20110606A true CR20110606A (es) 2012-01-12

Family

ID=42753372

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110606A CR20110606A (es) 2009-06-10 2011-11-16 Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales

Country Status (23)

Country Link
US (2) US8609097B2 (es)
EP (1) EP2440578B1 (es)
JP (2) JP2012529275A (es)
KR (1) KR101429367B1 (es)
CN (1) CN102459333B (es)
AR (1) AR077016A1 (es)
AU (1) AU2010257799B2 (es)
BR (1) BRPI1012993A2 (es)
CA (1) CA2762594C (es)
CL (1) CL2011003122A1 (es)
CO (1) CO6450613A2 (es)
CR (1) CR20110606A (es)
EC (1) ECSP11011514A (es)
HK (1) HK1166331A1 (es)
IL (1) IL216509A0 (es)
MA (1) MA33339B1 (es)
MX (1) MX2011012837A (es)
NZ (1) NZ596187A (es)
PE (1) PE20120543A1 (es)
RU (1) RU2536247C2 (es)
SG (1) SG176754A1 (es)
TW (1) TW201103560A (es)
WO (1) WO2010142423A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
HUE039167T2 (hu) 2009-06-10 2018-12-28 Chugai Pharmaceutical Co Ltd Tetraciklikus vegyületek
EP3698788A1 (en) 2010-08-20 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
WO2012049570A1 (en) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CN109265543B (zh) 2011-09-19 2022-04-26 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
SI2794654T1 (sl) * 2011-12-20 2019-08-30 Janssen Biotech, Inc. Protitelesa proti PHF-tau njihove uporabe
CA2854243A1 (en) * 2011-12-21 2013-06-27 Simone HOEGE Rapid method for cloning and expression of cognate antibody variable region gene segments
TWI700296B (zh) 2012-05-31 2020-08-01 公立大學法人大阪市立大學 失智症治療劑或預防劑
US9567395B2 (en) 2012-08-16 2017-02-14 Ipierian, Inc. Methods of treating a tauopathy
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
MX371442B (es) 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
DK2902029T3 (en) 2012-09-25 2018-10-29 Chugai Pharmaceutical Co Ltd RET INHIBITOR
LT2935326T (lt) * 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
WO2014096321A1 (en) * 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
CA2932958A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
KR102478887B1 (ko) 2014-04-25 2022-12-16 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 고용량 함유하는 제제
KR20220042486A (ko) 2014-04-25 2022-04-05 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CN107074938A (zh) * 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
RU2730668C2 (ru) * 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016114375A1 (ja) 2015-01-16 2016-07-21 中外製薬株式会社 併用医薬
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
WO2016168757A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
AU2016270858B2 (en) 2015-06-05 2022-04-28 Ac Immune Sa Anti-Tau antibodies and methods of use
PL3313877T3 (pl) * 2015-06-24 2020-11-02 F. Hoffmann-La Roche Ag Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
CA2991264C (en) * 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
UA124616C2 (uk) * 2015-07-06 2021-10-20 Юсб Біофарма Срл Зв'язуюче тау-білок антитіло
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
FI3334761T3 (fi) * 2015-08-13 2023-08-14 Univ New York Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
JP7116685B2 (ja) 2016-04-15 2022-08-10 エイチ． ルンドベック アー／エス ヒト化抗ｐａｃａｐ抗体及びそれらの使用
PE20190227A1 (es) 2016-07-12 2019-02-13 H Lundbeck As Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
KR102225178B1 (ko) 2017-10-16 2021-03-10 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
AU2019214370A1 (en) 2018-02-01 2020-07-30 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
CN112567033A (zh) 2018-07-03 2021-03-26 豪夫迈·罗氏有限公司 用于调节Tau表达之寡核苷酸
EP3829634A1 (en) 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
EP3848361A4 (en) 2018-09-04 2022-06-15 Chugai Seiyaku Kabushiki Kaisha TETRACYCLIC COMPOUND PRODUCTION PROCESS
US11702467B2 (en) 2020-06-25 2023-07-18 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6200768B1 (en) 1991-12-06 2001-03-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Method of screening for compounds that dissolve paired helical filaments
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP1876185A1 (en) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag An antibody which recognizes phosphorylated polypeptides

Also Published As

Publication number Publication date
JP6513617B2 (ja) 2019-05-15
EP2440578B1 (en) 2017-03-08
WO2010142423A2 (en) 2010-12-16
WO2010142423A3 (en) 2011-05-26
US20130310541A1 (en) 2013-11-21
RU2536247C2 (ru) 2014-12-20
MA33339B1 (fr) 2012-06-01
AU2010257799B2 (en) 2013-10-17
MX2011012837A (es) 2011-12-16
JP2012529275A (ja) 2012-11-22
PE20120543A1 (es) 2012-05-23
KR20120024952A (ko) 2012-03-14
HK1166331A1 (en) 2012-10-26
CL2011003122A1 (es) 2012-07-20
JP2017031176A (ja) 2017-02-09
CN102459333B (zh) 2015-07-15
CO6450613A2 (es) 2012-05-31
NZ596187A (en) 2013-11-29
AR077016A1 (es) 2011-07-27
AU2010257799A1 (en) 2011-12-01
SG176754A1 (en) 2012-01-30
US8609097B2 (en) 2013-12-17
CA2762594C (en) 2017-02-28
ECSP11011514A (es) 2012-01-31
TW201103560A (en) 2011-02-01
US9290567B2 (en) 2016-03-22
CA2762594A1 (en) 2010-12-16
KR101429367B1 (ko) 2014-08-11
IL216509A0 (en) 2012-02-29
US20110059093A1 (en) 2011-03-10
CN102459333A (zh) 2012-05-16
BRPI1012993A2 (pt) 2018-01-16
EP2440578A2 (en) 2012-04-18
RU2011152816A (ru) 2013-07-20

Similar Documents

Publication Publication Date Title
CR20110606A (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
UA111818C2 (uk) Антитіло проти csf-1r
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
GT201200189A (es) Antagonistas de pcsk9
GT200900167A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
NO20074238L (no) Fiksert dosering av HER-antistoffer
EA201490677A1 (ru) Связывающие антиген cd27l белки
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
NO20082749L (no) Fremgangsmate for fremstilling av ferri-succinylkasein
CO6390112A2 (es) Método para el tratamiento de la enfermedad de parkinson usando un bacterófago filamentoso
EA200900261A1 (ru) Применение эсцина
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
PE20091969A1 (es) ANTICUERPOS ANTI-PirB
CY1117251T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης της σκληροδερμιας
EA201270390A1 (ru) 1,2,4-триазин, который может быть использован в качестве ускорителя вулканизации, и способ его получения